ArdorComm Media Group

Saturday, February 7, 2026 5:04 AM

ICMR

NMC–ICMR to Roll Out PhD Programmes to Strengthen India’s Clinical Research and Medical Innovation

The National Medical Commission (NMC), in collaboration with the Indian Council of Medical Research (ICMR), is set to introduce new PhD programmes and intensify clinical research efforts to boost indigenous innovation in medical devices and pharmaceuticals. Announcing the initiative at the 3rd convocation of Bhaikaka University in Karamsad, Anand, NMC chairman Dr. Abhijat Sheth said the move aims to fortify India’s medical research landscape and encourage innovation-led healthcare advancements. He also shared that 18,000 additional medical seats have been approved nationwide, with parallel initiatives to expand faculty capacity and ensure equitable, high-quality medical education. Highlighting the growing burden of non-communicable diseases (NCDs), Dr. Sheth emphasised the urgent need for preventive healthcare, self-care practices and the ATCOM module on professionalism as part of the commission’s updated training framework. Citing lessons from the Covid-19 pandemic, he stressed the importance of preparing future medical professionals for public health emergencies. At the convocation, 496 students from undergraduate, postgraduate and PhD programmes received their degrees, while 10 students were honoured with gold medals for academic excellence. The ceremony was attended by BU president Dr. Gauri Trivedi, provost Dr. Abhay Dharamsi, and other officials. It also featured the 20th H M Patel Memorial Lecture, delivered by paediatrician and public health specialist Dr. Pravitra Mohan, who spoke on “Equitable Healthcare in India: Leading the Change.” Source: TNN

NMC–ICMR to Roll Out PhD Programmes to Strengthen India’s Clinical Research and Medical Innovation Read More »

CSIR, ICMR Chart Joint Roadmap to Boost Collaborative Health Research

The Council of Scientific and Industrial Research (CSIR) and the Indian Council of Medical Research (ICMR) held a high-level strategy meeting to advance a unified roadmap for collaborative health research, the Ministry of Science & Technology said on Tuesday. The session took place at the CSIR Science Centre in New Delhi and was co-chaired by N. Kalaiselvi, Director General of CSIR, and Rajiv Bahl, Director General of ICMR and Secretary, Department of Health Research. The two organisations reviewed progress on major joint initiatives, including CSIR-developed molecules progressing toward clinical trials, updates on ICMR-supported Centres of Advanced Research within CSIR labs, and implementation of large-scale national projects. The meeting also emphasised expanding wastewater surveillance for a wider range of pathogens across cities, hospitals and communities, aligning with the One Health Mission. Discussions included defining the roles of CSIR and ICMR in drug development, clinical trials, and leveraging ICMR’s large-animal toxicity testing infrastructure. The joint AcSIR–ICMR Ph.D. programme was also reviewed, with a focus on widening opportunities for young researchers by integrating ICMR and CSIR fellowship pathways. Both Dr. Kalaiselvi and Dr. Bahl stressed the importance of combining CSIR’s scientific and technological expertise with ICMR’s public health capabilities to deliver national-scale outcomes. They highlighted the need for structured, time-bound collaboration, particularly for co-developing technologies such as a digitally operated medical emergency drone service. Experts concluded by reaffirming plans to deepen cooperation in biomedical sciences, diagnostics, digital health, environmental surveillance, and other emerging healthcare domains. Source: IANS

CSIR, ICMR Chart Joint Roadmap to Boost Collaborative Health Research Read More »

ICMR Study Finds 1 in 9 People Tested Positive for Infectious Diseases in 2025

A recent nationwide analysis by the Indian Council of Medical Research (ICMR) has revealed that 11.1% of patients tested across India were found carrying infectious pathogens — roughly one in every nine individuals tested. The large-scale study, conducted through ICMR’s Virus Research and Diagnostic Laboratories (VRDL) network, aimed to track viral infections of public health concern. The five most commonly detected pathogens included Influenza A in acute respiratory infections (ARI/SARI), Dengue virus in cases of acute and haemorrhagic fever, Hepatitis A among jaundice patients, Norovirus in acute diarrhoeal disease (ADD) outbreaks, and Herpes Simplex Virus (HSV) in acute encephalitis syndrome (AES) cases. The ICMR report noted a rise in infection rates from 10.7% in the first quarter (January–March) to 11.5% in the second quarter (April–June) of 2025. Out of 2,28,856 samples tested in the first quarter, 24,502 showed the presence of pathogens, while 26,055 of 2,26,095 samples tested positive in the next quarter — marking an increase of 0.8 percentage points. A senior ICMR scientist cautioned that although the increase appears modest, it could be an early signal for seasonal outbreaks or emerging infections, underscoring the importance of continued surveillance. “Even small shifts in infection rates can serve as an early warning for potential epidemics. The VRDL network plays a vital role as India’s early detection system,” the scientist said. Between April and June 2025, 191 disease clusters were investigated, identifying infections such as mumps, measles, rubella, dengue, chikungunya, rotavirus, norovirus, varicella zoster virus, Epstein-Barr virus (EBV), and astrovirus. In comparison, 389 clusters were probed between January and March 2025, detecting a similar range of pathogens including hepatitis, influenza, Leptospira, and sexually transmitted infections (STIs). From 2014 to 2024, the VRDL network tested over 40 lakh samples, identifying pathogens in 18.8% of them. The network has seen rapid expansion — from 27 laboratories in 2014 to 165 labs across 31 states and Union Territories by 2025 — and has so far tracked 2,534 disease clusters nationwide. Source: PTI Photo Credit: Getty Images/iStockphoto

ICMR Study Finds 1 in 9 People Tested Positive for Infectious Diseases in 2025 Read More »

NMC Approves 10,650 New MBBS Seats, 41 New Medical Colleges Across India

In a major boost to India’s healthcare education landscape, the National Medical Commission (NMC) has approved 10,650 additional MBBS seats for the 2024–25 academic session, along with the establishment of 41 new medical colleges nationwide. This development aligns with Prime Minister Narendra Modi’s Independence Day 2024 commitment to create 75,000 new medical seats within five years, aimed at strengthening the country’s medical education and healthcare capacity. With these new additions, India now has a total of 816 medical colleges offering approximately 1,37,600 MBBS seats, including those under Institutes of National Importance (INIs). According to Dr. Abhijat Sheth, Chairperson of the NMC, the commission reviewed 170 proposals for seat expansion — 41 from government institutions and 129 from private colleges — ultimately approving the new capacity of 10,650 seats. The commission has also received over 3,500 applications for new and renewed postgraduate (PG) medical seats, with expectations of adding around 5,000 new PG seats, taking the national total to about 67,000. In total, the combined increase in UG and PG medical seats this year is projected to be nearly 15,000. Although the approval and counselling process experienced slight delays, NMC officials have assured that all procedures will conclude as per the designated timelines. A comprehensive blueprint for the upcoming academic year — including schedules for accreditation, examinations, and seat matrix approval — will be released soon. The application portal for 2025–26 is slated to open in early November. In a notable first, all appeals against the Medical Assessment and Rating Board (MARB) decisions were resolved without court intervention, reflecting greater efficiency in regulatory procedures. Dr. Sheth further revealed that the NMC is working to integrate clinical research into the MBBS curriculum through a proposed collaboration with the Indian Council of Medical Research (ICMR). This initiative aims to build stronger research infrastructure and encourage medical students to engage in clinical innovation and applied learning. These reforms represent a transformative step in India’s journey toward enhancing medical education quality, healthcare accessibility, and workforce readiness, in line with the government’s broader vision of a healthier, self-reliant India. Source: Indian Express

NMC Approves 10,650 New MBBS Seats, 41 New Medical Colleges Across India Read More »

Scientists Explore How Music Can Help Relieve Pain from Surgery and Illness

In the recovery ward at UC San Diego Health, nurse Rod Salaysay relies on more than just medical tools like a stethoscope or thermometer — he also uses his guitar and ukulele. Between post-surgery medications, Salaysay plays tunes at patients’ request, ranging from folk songs and classical pieces like Minuet in G Major to movie classics such as Somewhere Over the Rainbow. The results are often visible: patients smile, relax, and sometimes even require fewer painkillers. “In hospitals, pain, anxiety, and worry often feed into each other,” Salaysay explained. “Music can help break that cycle.” Over the last twenty years, hospitals and clinics worldwide have increasingly turned to music therapy — both live and recorded — as studies continue to reveal its power to ease physical and emotional pain. While music’s emotional influence has long been understood, scientists are only now uncovering how music-induced analgesia — the process by which music reduces pain perception — actually works. Although a melody can’t replace strong pain medication, research published in Pain and Scientific Reports shows that listening to music can lessen pain intensity and increase a person’s tolerance to discomfort. What seems crucial, researchers say, is that patients choose the music themselves and listen attentively, rather than passively. “Pain is incredibly complex,” said Adam Hanley, a psychologist at Florida State University. “It’s shaped by both the body’s sensations and our emotional and mental responses to those sensations.” Even with the same condition, two people might experience pain differently. Acute pain comes from immediate physical triggers, while chronic pain involves long-term changes in the brain that heighten sensitivity. “Pain is processed and interpreted by the brain,” said Dr. Gilbert Chandler, a chronic spinal pain expert from Tallahassee Orthopedic Clinic, “and the brain can amplify or reduce those signals.” Music, experts note, helps redirect attention away from pain. Studies suggest that preferred music is especially effective, even more than podcasts or generic playlists. “Music doesn’t just distract — it engages the whole brain,” said Caroline Palmer, a psychologist at McGill University. “That’s why it changes how people experience pain.” Indeed, Kate Richards Geller, a Los Angeles-based music therapist, explains that engaging with music activates nearly every brain region, easing not just pain but also isolation and anxiety. The use of music for pain relief dates back to the 19th century, when patients listened to melodies during dental procedures before anesthetics were common. Modern researchers continue to explore what makes it most effective. In one experiment at Erasmus University Rotterdam, scientists tested 548 participants across five music genres — classical, rock, pop, urban, and electronic — to measure how long they could withstand cold-induced pain. All genres helped, but none outperformed the others. “The best music is simply what you like,” said study co-author Dr. Emy van der Valk Bouman, noting that familiar songs may trigger memories and emotions that enhance resilience. Allowing patients to choose their music can also restore a sense of control and agency, said Claire Howlin of Trinity College Dublin, whose research shows that self-selected songs can boost pain tolerance. Hanley’s studies further indicate that focused, daily listening may gradually reduce chronic pain, offering an uplifting “emotional bump” without side effects. For many, it’s a powerful, drug-free remedy. Cecily Gardner, a jazz vocalist from California, said music helped her cope with illness and brought comfort to others in pain. “Music reduces stress, connects people,” she said, “and transports you somewhere better.” Source: AP

Scientists Explore How Music Can Help Relieve Pain from Surgery and Illness Read More »

ICMR Opens Door for Commercial Production of Next-Gen Malaria Vaccine

Ardorcomm news

The Indian Council of Medical Research (ICMR) has announced a major step forward in the fight against malaria by inviting expressions of interest (EoI) from eligible companies and manufacturers for the commercial production of a breakthrough malaria vaccine, AdFalciVax. Developed by the ICMR’s Regional Medical Research Centre in Bhubaneswar, this recombinant chimeric multi-stage vaccine targets Plasmodium falciparum, the deadliest malaria parasite, offering both individual protection and reduced community transmission. Pre-clinical validation of the vaccine technology was carried out in collaboration with ICMR-NIMR (National Institute of Malaria Research), other ICMR institutes, and the National Institute of Immunology in Delhi, which operates under the Department of Biotechnology. ICMR-RMRCBB will provide technical know-how and hands-on support throughout the vaccine production process to ensure a smooth and efficient pathway to commercialisation. Furthermore, ICMR’s team of seasoned scientists will assist in product development, study design, protocol development, data and results analysis, efficacy and safety assessments, and necessary improvements, based on mutual agreement with the collaborating partner. This initiative marks a significant stride in India’s effort to eliminate malaria through indigenous innovation and collaborative biotech development. Source: PTI

ICMR Opens Door for Commercial Production of Next-Gen Malaria Vaccine Read More »

India Nears Completion of Phase-3 Trials for Indigenous Dengue Vaccine: ICMR

India is on the cusp of a major public health milestone, with nearly 8,000 out of a targeted 10,000 participants already enrolled in Phase-3 clinical trials of the country’s first homegrown dengue vaccine, as per the Indian Council of Medical Research (ICMR). Dr. Manoj Murhekar, Director of ICMR’s National Institute of Epidemiology in Chennai, confirmed the progress in an interaction with The Hindu. The large-scale trials, which are being conducted at 20 different centres across the country, are testing the efficacy of DengiAll, a tetravalent vaccine developed by Panacea Biotec. This formulation aims to provide protection against all four known dengue virus serotypes that co-circulate in various parts of India. “An effective vaccine must be able to offer strong immunity against all four strains,” Dr. Murhekar emphasized. The ICMR is the primary funder of the project, with Panacea Biotec offering partial financial and technical support. Once vaccinated, participants will be monitored for a period of two years at locations including Delhi, Hyderabad, Pune, and Chennai. Currently, there is no approved vaccine or antiviral treatment for dengue in India, despite the disease being a recurring and widespread health issue. India remains among the top 30 countries most affected by dengue, according to the World Health Organization (WHO). By the end of 2023, over 129 countries had reported cases of dengue globally. The candidate vaccine, DengiAll, is derived from the TV003/TV005 tetravalent strain originally created by the U.S.-based National Institutes of Health. Panacea Biotec is one of three Indian firms granted access to the strain and has advanced furthest in the development process. The company completed early-stage (Phase-1 and 2) trials in 2018–19, which delivered encouraging results. It also holds a process patent for its unique formulation. The Union Health Ministry highlighted that the first participant in the Phase-3 trial received a dose at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences in Rohtak last year. Dengue poses a significant health threat in India. Although 75–80% of infections are asymptomatic, individuals can still spread the virus via Aedes mosquito bites. Among symptomatic cases—comprising about 20–25%—children face an elevated risk of severe outcomes, including hospitalization and death. In adults, the disease can escalate into life-threatening conditions such as dengue hemorrhagic fever and dengue shock syndrome. The challenge of controlling the virus is compounded by the presence of four distinct serotypes, each offering limited cross-immunity, making repeated infections common. With the success of this trial, India could soon have its first domestically developed and licensed dengue vaccine, marking a crucial step forward in the country’s fight against vector-borne diseases. Source: The Hindu  

India Nears Completion of Phase-3 Trials for Indigenous Dengue Vaccine: ICMR Read More »

No Proven Link Between COVID-19 Vaccines and Sudden Deaths, Confirms Union Health Ministry

The Union Ministry of Health and Family Welfare has clarified that there is no scientific evidence connecting COVID-19 vaccination with sudden or unexplained deaths in India. This conclusion is backed by comprehensive studies conducted by the Indian Council of Medical Research (ICMR) and the National Centre for Disease Control (NCDC). In an official statement, the Ministry emphasized that extensive investigations were carried out across the country by multiple research agencies to examine reports of sudden deaths, particularly among seemingly healthy young adults. Findings from these studies have consistently shown no direct association between COVID-19 vaccines and such fatalities. Two key studies have been pivotal in reaching this conclusion. The first, undertaken by ICMR’s National Institute of Epidemiology (NIE), is a multicentric matched case-control study titled “Factors associated with unexplained sudden deaths among adults aged 18–45 years in India.” Conducted across 47 tertiary hospitals in 19 states and union territories from May to August 2023, the research analyzed cases between October 2021 and March 2023. The outcome was clear: COVID-19 vaccination does not increase the risk of sudden death in young, otherwise healthy adults. The second study, still in progress, is being led by AIIMS, New Delhi, with ICMR’s collaboration and support. This prospective research—“Establishing the cause in sudden unexplained deaths in young”—aims to pinpoint the most common reasons behind such fatalities. Preliminary data reveals that heart attacks (myocardial infarctions) remain the leading cause of sudden death in this demographic, with no significant shift in trends compared to previous years. In many cases, genetic factors have also emerged as likely contributors. These studies offer valuable insights into sudden deaths among young individuals and provide reassurance about the safety of COVID-19 vaccines. Researchers highlight that deaths may stem from a range of issues, including underlying health conditions, genetic predispositions, and unhealthy lifestyles, rather than vaccination. Public health experts have strongly criticized unverified claims linking vaccines to sudden deaths, calling them unscientific and dangerous. Such misinformation not only lacks factual basis but also poses a serious risk to public trust and could foster vaccine hesitancy, undermining one of the most effective tools used during the pandemic to save lives. The government reaffirmed its commitment to science-driven public health policies and continued research to safeguard the health and well-being of all citizens. Source: ANI

No Proven Link Between COVID-19 Vaccines and Sudden Deaths, Confirms Union Health Ministry Read More »

Indigenous Kit Developed for Accurate, Rapid Detection of Nipah Virus: ICMR-NIV

In a significant stride for India’s healthcare innovation, the Indian Council of Medical Research (ICMR) has unveiled a homegrown rapid diagnostic kit capable of detecting the Nipah virus with complete accuracy. Designed for swift deployment in the field, the portable test delivers results in just 1 to 2 hours without the need for sophisticated laboratory equipment. Dr. Naveen Kumar, Director of ICMR’s National Institute of Virology (NIV) in Pune, highlighted the effectiveness of the kit, stating, “It is 100% sensitive and specific, relying on the amplification of the viral gene without requiring specialised machinery.” The cost-effective test is priced at ₹250 and is based on the Loop-mediated Isothermal Amplification (LAMP) assay technique. The Nipah virus, a highly lethal zoonotic pathogen with a mortality rate of approximately 50%, is primarily transmitted to humans from fruit bats. It can also spread via contaminated food or human-to-human contact. Symptoms of the infection range from mild flu-like signs to severe respiratory distress and encephalitis, often proving fatal. Recent outbreaks of the disease, particularly the 2023 episode in Kerala’s Kozhikode district, underscore the urgent need for swift and reliable diagnostics. ICMR is concurrently collaborating with Zydus Health Sciences (Ahmedabad) and the Translational Health Science and Technology Institute (Faridabad) on the development of monoclonal antibodies. Efforts are also underway to create an indigenous vaccine for the virus. NIV remains the only laboratory in India equipped to culture the Nipah virus, making it central to the country’s disease surveillance and response capabilities. Source: ANI

Indigenous Kit Developed for Accurate, Rapid Detection of Nipah Virus: ICMR-NIV Read More »

India Sees Uptick in COVID-19 Cases: Active Infections Near 4,000, Deaths Reported Across Key States

Ardorcomm news

India is witnessing a steady rise in COVID-19 infections, with active cases reaching 3,961 as of Monday, June 2—a jump of 566 cases from the previous day, according to data from the Ministry of Health and Family Welfare (MoHFW). The recent surge is driven primarily by states like Kerala, Maharashtra, and Delhi, which are reporting the highest case numbers. Since the start of the year, the country has registered 32 COVID-related deaths, including four in the last 24 hours. One fatality each was reported from Delhi, Kerala, Maharashtra, and Tamil Nadu. The deceased include a 22-year-old woman from Delhi with a history of post-tuberculosis complications and a 44-year-old man from Maharashtra suffering from acute respiratory distress and aortic valve problems. While Kerala confirmed another death, specific details are awaited. Delhi Records Steepest Daily Spike; Tamil Nadu, Karnataka Also Report Fatalities Delhi saw the most significant daily rise in active infections among major states, adding 47 new cases and logging one death. Tamil Nadu, with 189 active cases, reported the passing of a 25-year-old man with underlying bronchial asthma and acute kidney complications. Karnataka, currently reporting 253 active cases, recorded a fresh fatality, while Uttar Pradesh reported two deaths and has 157 active cases. In total, 16 states and Union Territories have recorded COVID-related deaths in 2025. However, the majority of cases remain mild, with limited hospital admissions. Kerala Leads in Caseload; Maharashtra, West Bengal Also on High Alert Kerala continues to report the highest number of active COVID-19 cases at 1,435, rising from 1,336 the previous day. Maharashtra follows with 506 active cases, and Delhi with 483. West Bengal has also seen a surge, reporting 331 active infections. Other notable figures include: Gujarat: 338 Karnataka: 253 Tamil Nadu: 189 Uttar Pradesh: 157 Rajasthan: 69 States like Madhya Pradesh (23), Haryana (28), and Odisha (12) have recorded smaller increases. In the last 24 hours, 203 patients have recovered, pushing the total number of recoveries and migrations this year to 2,188. Authorities Urge Caution, Not Panic Health experts and officials maintain that the situation is under control, emphasizing that most new cases are mild and manageable at home. Dr. Rajiv Behl, Director General of the Indian Council of Medical Research (ICMR), reassured the public that while increased vigilance is necessary, there’s no immediate cause for alarm. The rise in cases coincides with the detection of new Omicron sub-variants—LF.7, XFG, JN.1, and NB.1.8.1—identified in genome sequencing studies from western and southern India. These have been classified by the World Health Organization as “Variants Under Monitoring,” indicating they don’t currently pose a significant global threat. Preparedness Measures in Place as Precaution In response, state health departments—particularly in Delhi, Maharashtra, and Kerala—are ramping up hospital readiness and reviewing medical supply logistics. Citizens, especially vulnerable groups such as the elderly and those with pre-existing health issues, are being encouraged to wear masks in crowded or poorly ventilated settings. Experts stress that while the virus is spreading faster due to more contagious but less severe sub-variants, preventive strategies such as timely testing, vaccination, and community awareness remain key to containing its impact. Though the overall caseload is still far lower than during peak waves, the recent tenfold increase over two weeks underscores the need for continued monitoring, public cooperation, and proactive measures to avoid another significant outbreak. Source: Economic Times Photo Credit: iStock   

India Sees Uptick in COVID-19 Cases: Active Infections Near 4,000, Deaths Reported Across Key States Read More »